文献速递眼底病与葡萄膜炎白内障与屈光手术

玻璃体腔抗VEGF注射对白内障发生的影响

Impact of Intravitreal Anti-VEGF Injections on Cataract Development.
PubMed 文献 · Ophthalmology · 2026-03-11

这项回顾性干预性病例系列研究纳入双眼晶状体均透明的603例患者,比较单眼接受≥12次抗VEGF注射眼与未治疗对侧眼的白内障手术发生率。中位随访74个月,注射眼10年累积白内障手术发生率为40.7%,对侧眼为7.2%;注射眼风险显著升高(HR 8.174),高龄亦与风险升高相关。

要点

  • 单眼≥12次抗VEGF注射者,注射眼10年白内障手术累积发生率为40.7%,对侧眼为7.2%。
  • 注射眼白内障手术风险显著升高(HR 8.174,95%CI 5.767-11.586)。
  • 注射眼核性、皮质性和后囊下混浊分级均显著更高,以后囊下差异最大。

核心结论

  • 长期玻璃体腔抗VEGF治疗与需手术干预的白内障发生风险显著增加相关。

研究设计与样本

  • 回顾性、干预性病例系列,纳入基线双眼均为有晶状体眼且接受≥12次单眼抗VEGF注射的患者。
  • 共603例患者,中位随访74个月,比较注射眼与未治疗对侧眼的白内障手术发生率。
  • 采用Kaplan-Meier生存分析评估累积发生率。

主要发现

  • 注射眼10年白内障手术累积发生率为40.7%(95%CI 35.9%-45.1%),对侧眼为7.2%(95%CI 4.1%-10.3%)。
  • 注射眼与白内障手术风险升高相关(HR 8.174,95%CI 5.767-11.586)。
  • 年龄增大亦与白内障手术风险升高相关(HR 1.069,95%CI 1.052-1.086)。
  • 手术时注射眼核性、皮质性和后囊下混浊分级均显著高于对侧眼(P < 0.001),以后囊下混浊差异最大。

关键数值与推荐

  • 纳入标准:基线双眼有晶状体眼且接受≥12次单眼抗VEGF注射。
  • 主要结局指标:注射眼相较对侧眼发生白内障手术的风险比(HR)及95%CI。

临床怎么用

  • 对长期接受抗VEGF注射的患者,应关注白内障发生风险并在随访中评估晶状体状态。
  • 注射眼出现后囊下混浊加重的可能性较大,手术规划时需考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the association between intravitreal anti-VEGF injections and incident cataract surgery. DESIGN: Retrospective, interventional case series. PARTICIPANTS: Patients with phakic lens status in both eyes at baseline who received 12 or more unilateral anti-VEGF injections. METHODS: Electronic medical records were analyzed to compare the incidence of cataract surgery between injected eyes (receiving anti-VEGF treatment) and untreated fellow eyes. Cumulative incidence was assessed using the Kaplan-Meier survival analysis. Lens opacity grades at the time of surgery and change in best-corrected visual acuity before and after the surgery also were analyzed. MAIN OUTCOME MEASURES: Hazard ratio (HR) and 95% confidence interval (CI) for incident cataract surgery in the injected eye compared with the fellow eye. RESULTS: A total of 603 patients were followed up for a median of 74 months. The 10-year cumulative incidence of cataract surgery was 40.7% (95% CI, 35.9%-45.1%) and 7.2% (95% CI, 4.1%-10.3%) in the injected and fellow eyes, respectively. The injected eye (HR, 8.174; 95% CI, 5.767-11.586) and older age (HR, 1.069; 95% CI, 1.052-1.086) were associated with an increased risk of cataract surgery. At the time of surgery, all lens opacity grades, including nuclear, cortical, and posterior subcapsular, were significantly higher in injected eyes (P < 0.001 for all), with the greatest difference observed in posterior subcapsular opacity. CONCLUSIONS: Long-term intravitreal anti-VEGF treatment was associated with a significantly increased risk of cataract developing for which surgical intervention was performed. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Choi J, Choi E, Kang SW, et al. Impact of Intravitreal Anti-VEGF Injections on Cataract Development. Ophthalmology. 2026. PMID: 41825596. doi:10.1016/j.ophtha.2026.03.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。